RxDoctor Payments Data

Shamil Patel, MD

Ophthalmology · Glendale, AZNPI 1821298134

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $76,930 of the $116,223 with a category attached, or 66.2%. Nova Eye, Inc. accounts for 64.1% of it on its own, with 28 other manufacturers making up the rest. 2025 is the largest year on record at $35,088, more than ten times the $1,690 reported in 2019. Among ophthalmology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$116,223in general payments, 2019–2025

Across 356 payments — averaging $326.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nova Eye, Inc.$75K
  • Glaukos Corporation$29K
  • Aerie Pharmaceuticals, Inc.$3K
  • AbbVie$3K
  • Alcon$2K
  • Bausch & Lomb Americas Inc.$2K
  • plus $4K from 23 others
$341,009in research payments, 2019–2025

Across 34 payments — averaging $10,030 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Glaukos Corporation$341K

What the payments were for

  • Consulting fees$76,93066%
  • Speaking & faculty fees$9,7508%
  • Travel & lodging$13,28911%
  • Food & beverage$16,25414%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$116,223 in reported general payments places this provider in the 95th percentile of 310 ophthalmology providers in Arizona.

See all ophthalmology providers in Arizona

Medicare billing

Part B allowed, 2024
$612,571
Medicare patients
788
Services billed
3,873

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost298$134,782
RocklatanNetarsudil Mesylat/Latanoprost188$92,061
VyzultaLatanoprostene Bunod123$61,033
CombiganBrimonidine Tartrate/Timolol94$37,116
RhopressaNetarsudil Mesylate84$35,368
Alphagan PBrimonidine Tartrate83$28,768
SimbrinzaBrinzolamide/Brimonidine Tart78$26,997
RestasisCyclosporine30$24,219
Prednisolone Acetate417$18,134
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol115$17,918
Dorzolamide-TimololDorzolamide/Timolol/Pf101$17,091
Brinzolamide87$14,661
Travoprost100$13,982
Brimonidine Tartrate316$12,784
TafluprostTafluprost/Pf55$10,180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P, Restasis$2,757$224,885505 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$3,189$127,430272 claims
Bausch & Lomb Americas Inc.Vyzulta$1,515$61,033123 claims
AlconSimbrinza$1,872$26,99778 claims
Akorn, Inc.Zioptan$15$4,72515 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$365$1,71912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 310 ophthalmology providers in Arizona.

Other ophthalmology in Glendale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →